Emergent BioSolutions Inc. (EBS) › Total AssetsEmergent BioSolutions Inc. (EBS) — Total AssetsAnnual figures by period end, from SEC filings.2010-12-31: $500.32M2011-12-31: $546.86M2012-12-31: $564.23M2013-12-31: $626.63M2014-12-31: $938.69M2015-12-31: $1.04B2016-12-31: $970.11M2017-12-31: $1.07B2018-12-31: $2.23B2019-12-31: $2.33B2020-12-31: $2.88B2021-12-31: $2.96B2022-12-31: $3.17B2023-12-31: $1.82B2024-12-31: $1.39B2025-12-31: $1.32B$1.32B2010-12-31Total Assets (USD)2025-12-31Period endedTotal AssetsChange YoYSource filing2025-12-31$1.32B-5.1%2026-02-27Balance as of period end2024-12-31$1.39B-23.8%2026-02-27Balance as of period end2023-12-31$1.82B-42.4%2025-03-04Balance as of period end2022-12-31$3.17B+7.1%2024-03-08Balance as of period end2021-12-31$2.96B+2.6%2023-12-11Balance as of period end2020-12-31$2.88B+23.9%2022-02-25Balance as of period end2019-12-31$2.33B+4.4%2021-02-19Balance as of period end2018-12-31$2.23B+108.3%2020-02-25Balance as of period end2017-12-31$1.07B+10.3%2019-02-22Balance as of period end2016-12-31$970.11M-6.5%2018-02-23Balance as of period end2015-12-31$1.04B+10.5%2017-02-28Balance as of period end2014-12-31$938.69M+49.8%2016-02-29Balance as of period end2013-12-31$626.63M+11.1%2016-02-29Balance as of period end2012-12-31$564.23M+3.2%2015-03-09Balance as of period end2011-12-31$546.86M+9.3%2014-03-10Balance as of period end2010-12-31$500.32M—2013-03-08Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)